无脾或脾功能异常2-17岁儿童接种肺炎球菌不可分型流感嗜血杆菌蛋白D结合疫苗(PHiD-CV)的免疫原性、安全性和反应原性:一项3期研究
在波兰和俄罗斯开展3期多中心开放标签对照研究,无脾或脾功能异常儿童按2-4、5-10、11-17岁分层入组,2-4岁组设健康对照。未接种过肺炎球菌疫苗者接种2剂PHiD-CV,曾接种者接种1剂。结果显示疫苗在该人群有免疫原性且耐受良好,未发现安全性问题。
要点
- 接种后所有高危儿童对各疫苗血清型和6A血清型抗体浓度≥0.2µg/mL
- 对19A血清型至少94.4%的高危儿童抗体浓度≥0.2µg/mL
- 未发现安全性问题,报告1例非致死性严重不良事件(呼吸道感染,判定与疫苗无关)
核心结论
- PHiD-CV在2-17岁无脾或脾功能异常儿童中具有免疫原性且耐受良好。
研究设计与样本
- 3期、多中心、开放标签、对照研究,在波兰和俄罗斯开展,入组无脾或脾功能异常儿童(年龄分层:2-4岁、5-10岁、11-17岁),2-4岁高危组入组年龄匹配的健康儿童作为对照。
- 未接种过任何肺炎球菌疫苗的儿童接种2剂PHiD-CV(间隔≥2个月),曾接种肺炎球菌疫苗的儿童接种1剂。
- 共52名儿童接种疫苗(18名高危曾接种、28名高危未接种、6名对照未接种),其中45名(分别为18、23、4名)纳入符合方案免疫原性队列。
主要发现
- 接种后(曾接种者第1剂后、未接种者第2剂后),所有高危儿童对每种疫苗肺炎球菌血清型和疫苗相关血清型6A的抗体浓度≥0.2µg/mL,对疫苗相关血清型19A至少94.4%达到该阈值。
- 观察到抗体几何平均浓度升高。
- 对大多数血清型,所有高危儿童接种后调理吞噬活性(OPA)滴度≥8,并观察到OPA几何平均滴度升高。
- 1名高危未接种儿童报告1例非致死性严重不良事件(呼吸道感染,判定与疫苗无关)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunization with pneumococcal vaccines is an important prophylactic strategy for children with asplenia or splenic dysfunction, who are at high risk of bacterial infections (including S. pneumoniae). This study aimed to assess immunogenicity and safety of pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, GSK) in this at-risk population. METHODS: This phase III, multi-centre, open-label, controlled study, in which at-risk children with asplenia or splenic dysfunction were enrolled (age strata: 2-4, 5-10 and 11-17years), was conducted in Poland and the Russian Federation. For the 2-4years at-risk group, healthy age-matched children were enrolled as control. Unprimed children (not previously vaccinated with any pneumococcal vaccine) received 2 PHiD-CV doses (≥2months apart) and pneumococcal vaccine-primed children received 1 dose. Immune responses were assessed pre-vaccination and one month post-each dose. Solicited and unsolicited adverse events (AEs) were recorded for 4 and 31days post-vaccination, respectively, and serious AEs (SAEs) throughout the study. RESULTS: Of 52 vaccinated children (18 at-risk primed, 28 at-risk unprimed and 6 control unprimed), 45 (18, 23 and 4, respectively) were included in the according-to-protocol cohort for immunogenicity. Post-vaccination (post-dose 1 in primed and post-dose 2 in unprimed children), for each vaccine pneumococcal serotype and vaccine-related serotype 6A all at-risk children had antibody concentrations ≥0.2µg/mL, and for vaccine-related serotype 19A at least 94.4%. Increases in antibody geometric mean concentrations were observed. For most serotypes, all at-risk children had post-vaccination opsonophagocytic activity (OPA) titers ≥8 and increases in OPA geometric mean titers were observed. No safety concerns were raised. One non-fatal SAE (respiratory tract infection, considered not vaccine-related) was reported by one at-risk unprimed child. CONCLUSION: PHiD-CV was immunogenic and well tolerated in 2-17-year-old children with asplenia or splenic dysfunction. Clinical Trial Registry: www.clinicaltrials.gov, NCT01746108.
引用
- Szenborn L, Osipova IV, Czajka H, et al. Immunogenicity, safety and reactogenicity of the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in 2-17-year-old children with asplenia or splenic dysfunction: A phase 3 study. Vaccine. 2017. PMID: 28866290. doi:10.1016/j.vaccine.2017.08.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。